Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  MDxHealth    MDXH   BE0003844611

MDXHEALTH (MDXH)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 05:35:18 pm
1.79 EUR   -3.24%
08/27MDXHEALTH SA : half-yearly earnings release
2017MDXHEALTH SA : annual earnings release
2013MDXHEALTH SA : quaterly earnings release
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
1.83(c) 1.858(c) 1.9(c) 1.85(c) 1.79(c) Last
96 381 106 065 80 845 55 222 65 274 Volume
-6.15% +1.53% +2.26% -2.63% -3.24% Change
More quotes
Financials (EUR)
Sales 2018 31,6 M
EBIT 2018 -18,4 M
Net income 2018 -22,1 M
Finance 2018 28,1 M
Yield 2018 -
Sales 2019 45,9 M
EBIT 2019 -12,6 M
Net income 2019 -15,2 M
Finance 2019 31,0 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 2,63x
EV / Sales2019 1,74x
Capitalization 111 M
More Financials
Company
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic assays and service testing for cancer assessment and the personalized treatment of patients. The activity is organized around two product families: - Clinical Molecular Diagnostics (ClinicalMDx)... 
More about the company
Surperformance© ratings of MDxHealth
Trading Rating : Investor Rating :
More Ratings
Latest news on MDXHEALTH
11/27MDXHEALTH : Announces Approval for SelectMDx for Prostate Cancer by New York Sta..
AQ
11/26MDXHEALTH (R) : MDxHealth Announces Approval for SelectMDx for Prostate Cancer b..
PU
11/26MDXHEALTH (R) : MDxHealth Announces Approval for SelectMDx for Prostate Cancer ..
GL
11/07MDXHEALTH (R) : SelectMDx improves prostate biopsy decision-making in urology pr..
PU
11/07MDXHEALTH (R) : SelectMDx improves prostate biopsy decision-making in urology p..
GL
10/23MDXHEALTH : Provides Business Update for the first nine months of 2018
GL
10/23MDXHEALTH : Provides Business Update for the first nine months of 2018
AQ
10/18MDXHEALTH : Shareholder Transparency Declaration MDxHealth
AQ
10/18MDXHEALTH SHAREHOLDER TRANSPARENCY D :
AQ
10/17MDXHEALTH SHAREHOLDER TRANSPARENCY D :
GL
More news
Analyst Recommendations on MDXHEALTH
More recommendations
Sector news : Biotechnology & Medical Research - NEC
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/13Lilly, Incyte Get FDA Fast-Track Designation for Baricitinib in Systemic Lupu..
DJ
12/10Almost half of S&P 500 stocks in a bear market
RE
12/10ROCHE : Gilead Sciences snares Roche veteran O'Day as CEO
RE
12/10LONZA : to Establish Biomanufacturing Base in China
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart MDXHEALTH
Duration : Period :
MDxHealth Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MDXHEALTH
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 4,84 €
Spread / Average Target 162%
EPS Revisions
Managers
NameTitle
Jan Groen President, CEO & Executive Director
Koen Hoffman Chairman
Jean-Marc Roelandt Chief Financial Officer & Executive Vice President
Michael K. Brawer Chief Medical Officer & Executive Vice President
Rudi M. Mariën Non-Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MDXHEALTH-42.37%126
IQVIA HOLDINGS INC24.11%24 306
CELLTRION, INC.--.--%24 149
LONZA GROUP16.86%23 031
INCYTE CORPORATION-28.95%14 320
SEATTLE GENETICS, INC.14.02%9 843